Stabilized microcapsules, method of their preparation and uses thereof
The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.
1. A microcapsule comprising a core encapsulated by a silica based shell, wherein said core comprises solid benzoyl peroxide (BPO), wherein said benzoyl peroxide is released at a dissolution rate of between 12%-60% weight/h as measured in a medium of 55%:45% mixture of water and acetonitrile at ambient temperature, and wherein said microcapsule is prepared by a process comprising:
a) contacting solid benzoyl peroxide particulate matter, with a first cationic additive being a cationic surfactant, to obtain a dispersion in an aqueous medium, said particulate matter having positive charges on its surface;
b) adding an aqueous solution comprising silicate salt to said dispersion of said particulate matter, under conditions wherein said silicate salt precipitates onto the surface of the particulate matter, and acidifying to thereby form a solid, water-insoluble particulate matter that has a metal oxide layer coated thereon;
c) contacting, in a medium consisting of an aqueous medium, the particulate matter coated with a silica based layer of the preceding step with a surface adhering additive being one or both of (i) a second cationic additive being a cationic polymer and (ii) a non-ionic additive, to obtain a dispersion of said coated particulate matter having an adhering additive on the surface thereof in said aqueous medium;
d) bringing the dispersion obtained in step (c) into contact with an aqueous solution of a sodium silicate, under conditions wherein said sodium silicate precipitates onto the surface of said coated particulate matter, and acidifying to thereby form a solid, water-insoluble particulate matter that has a further silica based layer coated thereon;
e) repeating steps (c) and (d) between 3-50 times at a temperature of between 28° C. to 40° C.; and
f) optionally, after completion of step (e), aging the dispersion to obtain said encapsulated benzoyl peroxide.
2. The microcapsule according to claim 1 , wherein said cationic surfactant is cetyltrimethyl ammonium chloride (CTAC) or wherein said cationic polymer is poly(dimethyldiallylammonium chloride) (PDAC), or a combination thereof.
3. The microcapsule according to claim 1 , wherein said step (e) is between 5-7 times (i.e. steps (c) and (d) are repeated between 5-7 times).
4. The microcapsule according to claim 1 , wherein said acidifying step, in step (b), comprises addition of an acidic solution comprising at least one weak acid and said metal oxide salt is a silicate salt.
5. The microcapsule according to claim 4 , wherein said weak acid comprises citric acid, lactic acid or a mixture thereof.
6. The microcapsule according to claim 1 , wherein the average diameter of said microcapsule is less than 50 micrometers.
7. The microcapsule according to claim 1 , wherein the thickness of the silica based shell ranges between 25 nm and 3000 nm.
8. The microcapsule according to claim 1 , wherein said microcapsule is stable for a period of between about 2 weeks to about 3 years at room temperature.
9. A suspension comprising the microcapsule according to claim 1 .
10. A pharmaceutical composition comprising the microcapsule according to claim 1 , and a pharmaceutically acceptable carrier or excipient.
11. A pharmaceutical composition comprising the suspension of claim 9 , and a pharmaceutically acceptable carrier or excipient.
12. The pharmaceutical composition according to claim 10 , wherein the carrier is in a form of an ointment, a cream, a lotion, an oil, a solution, an emulsion, a gel, a paste, a milk, an aerosol, a powder or a foam.
13. The pharmaceutical composition according to claim 11 , wherein the carrier is in a form of an ointment, a cream, a lotion, an oil, a solution, an emulsion, a gel, a paste, a milk, an aerosol, a powder or a foam.
14. The pharmaceutical composition according to claim 10 , wherein the microcapsules have microencapsulation efficiency of at least 75%.
15. The pharmaceutical composition according to claim 11 , wherein the microcapsules have microencapsulation efficiency of at least 75%.
16. A pharmaceutical composition comprising the microcapsules according to claim 1 , wherein the benzoyl peroxide is in an amount of about 3% by weight of said composition and the composition further comprises microcapsules comprising tretinoin or a pharmaceutically acceptable salt thereof in an amount of about 0.1% by weight of said composition; and a pharmaceutically acceptable carrier or excipient.
17. A pharmaceutical composition comprising microcapsules comprising benzoyl peroxide according to claim 1 , wherein the benzoyl peroxide is in an amount of about 3% by weight of said composition; and the composition further comprises microcapsules comprising tretinoin or a pharmaceutically acceptable salt thereof in an amount of about 0.1% by weight of said composition and; and a pharmaceutically acceptable carrier or excipient, wherein the microcapsules comprising tretinoin comprise a core encapsulated by a shell, wherein said core comprises tretinoin in a solid form; wherein the microencapsulation efficiency of the tretinoin is at least 90%.
18. The pharmaceutical composition according to claim 17 , wherein said tretinoin is at a concentration of above 14% w/w within the core.
19. The pharmaceutical composition according to claim 16 , wherein the tretinoin dissolution rate is between 5% to 35% weight/h as measured in a medium of 30%:70% V/V mixture of water: isopropyl alcohol at 32° C. and wherein the BPO dissolution rate is between 12% to 60% weight/h as measured in a medium of 55%:45% mixture of water:acetonitrile at ambient temperature.
20. The pharmaceutical composition according to claim 17 , wherein the tretinoin dissolution rate is between 5% to 35% weight/h as measured in a medium of 30%:70% V/V mixture of water: isopropyl alcohol at 32° C. and wherein the BPO dissolution rate is between 12% to 60% weight/h as measured in a medium of 55%:45% mixture of water:acetonitrile at ambient temperature.
21. The pharmaceutical composition according to claim 16 , wherein the microcapsules of the benzoyl peroxide have microencapsulation efficiency of at least 75% and the microcapsules of the tretinoin have microencapsulation efficiency of at least 90%.
22. The pharmaceutical composition according to claim 17 , wherein after two weeks storage at 40° C. and 75% relative humidity a concentration of all-trans 5,6-epoxy retinoic acid is less than 1% by weight of the initial tretinoin amount prior to storage.
23. The pharmaceutical composition according to claim 17 , wherein the microcapsules of the benzoyl peroxide have microencapsulation efficiency of at least 75%, and the microcapsules of the tretinoin have microencapsulation efficiency of at least 90%.
24. The pharmaceutical composition according to claim 16 , wherein after two weeks storage at 40° C. and 75% relative humidity a concentration of all-trans 5,6-epoxy retinoic acid is less than 1% by weight of the initial tretinoin amount prior to storage.
25. A method for treating a skin disease, disorder or condition in a subject in need thereof, said method comprising topically administering to said subject a pharmaceutical composition according to claim 10 , wherein said skin disease, disorder or condition is selected from the group consisting of: acne, psoriasis, seborrhea, contact dermatitis, rosacea, and any combination thereof.
26. A method for treating a skin disease, disorder or condition in a subject in need thereof, said method comprising topically administering to said subject a pharmaceutical composition according to claim 11 , wherein said skin disease, disorder or condition is selected from the group consisting of: acne, psoriasis, seborrhea, contact dermatitis, rosacea, and any combination thereof.
27. A method for treating a skin disease, disorder or condition in a subject in need thereof, said method comprising topically administering to said subject a composition according to claim 16 , wherein said skin disease, disorder or condition is selected from the group consisting of: acne, psoriasis, seborrhea, contact dermatitis, rosacea, and any combination thereof.
28. The method according to claim 27 , wherein the microcapsules of the benzoyl peroxide have microencapsulation efficiency of at least 75%; and the microcapsules of the tretinoin have microencapsulation efficiency of at least 90%.
29. A method for treating a skin disease, disorder or condition in a subject in need thereof, said method comprising topically administering to said subject a composition according to claim 17 , wherein said skin disease, disorder or condition is selected from the group consisting of: acne, psoriasis, seborrhea, contact dermatitis, rosacea, and any combination thereof.
30. The method according to claim 29 , wherein the microcapsules of the benzoyl peroxide have microencapsulation efficiency of at least 75%, and the microcapsules of the tretinoin have microencapsulation efficiency of at least 90%.
31. A method for treating rosacea in a subject in need thereof, said method comprising topically administering to said subject a pharmaceutical composition according to claim 10 , wherein the microcapsules have microencapsulation efficiency of at least 75%.
32. A method for treating rosacea in a subject in need thereof, said method comprising topically administering to said subject a pharmaceutical composition according to claim 11 , wherein the microcapsules have microencapsulation efficiency of at least 75%.